TCR2 Therapeutics Inc. Profile Avatar - Palmy Investing

TCR2 Therapeutics Inc.

TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (T…

Biotechnology
US, Cambridge [HQ]

Document Reader

Click To Read:

DEF 14-A Proxies

Not a single DEF 14-A proxy doc.

10-K Filings

Not a single 10-K doc.

10-Q Filings

Not a single 10-Q doc.

LDA 1/2 Filings [Lobbying]

Not a single LDA doc.

End of TCRR's Analysis
CIK: 1750019 CUSIP: 87808K106 ISIN: US87808K1060 LEI: - UEI: -
Secondary Listings
TCRR has no secondary listings inside our databases.